Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Solid tumors generally require a vascularized connective tissue stroma if they are to grow beyond minimal size. They generate that stroma in part by secreting vascular endothelial growth factor (VEGF), a potent vascular permeability and angiogenic factor. Increased vascular permeability leads to deposition of a provisional fibrin stroma, which supports tumor, connective tissue, and inflammatory cell migration and plays an active role in the formation of mature vascularized stroma. Vascular endothelial growth factor-induced tumor blood vessels are heterogeneous, of at least 6 distinct types, and develop linearly over time. They include both angiogenic (mother vessels, glomeruloid microvascular proliferations, vascular malformations, capillaries) and arteriovenogenic (feeding arteries, draining veins) blood vessels. Attacking the tumor vasculature with drugs that target VEGF or its receptors (VEGFR) has come into vogue but has been less effective than had been hope for. One reason for this is that anti-VEGF/VEGFR therapy attacks only a subset of tumor blood vessels, the earliest to form. New targets on late-forming blood vessels such as feeding arteries would be useful in helping antivascular cancer therapy fulfill its promise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 1×
“Finally, therapy targeting VEGF and its receptors has found a place in treating human cancer.(60,61) Unfortunately, however, anti-VEGF/VEGF receptor therapy has not been the cureall that was hoped for.”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“As a consequence, the fibrin gel deposited by tumors is degraded and is replaced over time by the ingrowth of fibroblasts and new blood vessels; these give rise to a loose and highly vascular connective tissue that resembles the “granulation tissue” of healing wounds.(25,32) As blood vessels regress and new collagen i…”
BackgroundSelf-citationModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Copyright © 2015 Wolters Kluwer is, MV, and FA, and DV precursors,(69,79,80) but is much less effective against tumors with an established vasculature rich in “late” blood vessels.(81) Human cancers, of course, have grown for many months or years before detection and are therefore presumably supplied by many late bloo…”
BackgroundTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“Furthermore, because anti-VEGF/VEGFR therapy is only partially successful, it leaves behind a population of ischemic tumor and stromal cells that respond to hypoxia by up-regulating the synthesis not only of VEGF but also of other growth factors.(75) These growth factors then stimulate tumor growth as well as new bloo…”
BackgroundBrown, L. F., Yeo, K. T., Berse, B., Yeo, T. K., Senger, D. R., Dvorak, H. F., & van de Water, L. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.5.1375 · Cited by 878 · cited 1×
“This very same sequence of events takes place in the physiological process of corpus luteum formation (a form of wound healing)(44) and in other examples of wound healing such as skin wounds and myocardial infarcts where VEGF comes to be overexpressed.(45,46) In short, tumors have preempted and subverted a fundamental…”
BackgroundSelf-citationAn interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 1×
“Another is that Bv8 and IL-17–expressing TH stromal cells impede the response to treatment.(74) Furthermore, because anti-VEGF/VEGFR therapy is only partially successful, it leaves behind a population of ischemic tumor and stromal cells that respond to hypoxia by up-regulating the synthesis not only of VEGF but also o…”
BackgroundVascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
Cited by
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710754114 · Cited by 138
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy
Zhu, S., Yang, N., Wu, J., Wang, X., Wang, W., Liu, Y.-J., & Chen, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104980 · Cited by 71
Torok, S., Rezeli, M., Kelemen, O., Vegvari, A., Watanabe, K., Sugihara, Y., Tisza, A., Marton, T., Kovacs, I., Tovari, J., et al. (2017) · Theranostics · doi:10.7150/thno.16767 · Cited by 70
“The previously described resistance mechanisms include the development of a more malignant phenotype associated with therapy-induced hypoxia, VEGF-independent endothelial growth driven by various pro-angiogenic cytokines, the mobilization of bone marrow-derived proangiogenic hematopoietic cells or endothelial progenit…”
BackgroundResult
Metadata
- Authors
- Dvorak, H. F.
- Venue
- The Cancer Journal
- Published
- 2015-07
- Volume
- 21
- Issue
- 4
- Pages
- 237-243
- ISSN
- 1528-9117 (ISSN-L)
- OpenAlex
- W940185179
- Cited by
- 116
- References
- 9
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. https://app.cochat.ai/papers/10.1097/ppo.0000000000000124
- The paper
- Dvorak, H. F. (2015). Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. The Cancer Journal. https://doi.org/10.1097/ppo.0000000000000124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.